Vitamin E and Alzheimer disease: The basis for additional clinical trials

230Citations
Citations of this article
135Readers
Mendeley users who have this article in their library.

Abstract

Many lines of evidence suggest that oxidative stress is important in the pathogenesis of Alzheimer disease. In particular, β-amyloid, which is found abundantly in the brains of Alzheimer disease patients, is toxic in neuronal cell cultures through a mechanism involving free radicals. Vitamin E prevents the oxidative damage induced by β-amyloid in cell culture and delays memory deficits in animal models. A placebo-controlled, clinical trial of vitamin E in patients with moderately advanced Alzheimer disease was conducted by the Alzheimer's Disease Cooperative Study. Subjects in the vitamin E group were treated with 2000 IU (1342 α-tocopherol equivalents) vitamin E/d. The results indicated that vitamin E may slow functional deterioration leading to nursing home placement. A new clinical trial is planned that will examine whether vitamin E can delay or prevent a clinical diagnosis of Alzheimer disease in elderly persons with mild cognitive impairment.

Cite

CITATION STYLE

APA

Grundman, M. (2000). Vitamin E and Alzheimer disease: The basis for additional clinical trials. In American Journal of Clinical Nutrition (Vol. 71). American Society for Nutrition. https://doi.org/10.1093/ajcn/71.2.630s

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free